PhaseBio Pharmaceuticals, Inc. Initiates a Multicenter, Randomized Placebo and Active Comparator Controlled Phase 2b Trial to Evaluate Use of Glymera for the Treatment of Uncontrolled Type 2 Diabetes
8/21/2012 9:54:55 AM
MALVERN, Pa.--(BUSINESS WIRE)--PhaseBio Pharmaceuticals, Inc., a privately held, clinical-stage biotechnology company developing drugs to treat diabetes, metabolic disease and cardiovascular disease, announced today that it has initiated dosing in a multicenter (USA), randomized, placebo and active comparator controlled Phase 2b study that will enroll approximately 600 patients with type 2 diabetes (hemoglobin A1c 7% - 11%) inadequately controlled with diet and exercise, metformin, a sulfonylurea or a combination of metformin/sulfonylurea. The study will evaluate the efficacy and safety of three doses of once weekly Glymera compared to matched placebo as well as an active comparator. This study is targeted to complete by 3Q2013.
comments powered by